FEB 01, 2017 10:28 AM PST

Exposing HIV Reservoirs For Killer T Cells

WRITTEN BY: Kara Marker

HIV infections are particularly difficult to clear for many reasons, one being that they hide out in the immune system’s own cells. In fact, a specific type of cells called follicular helper T cells (Tfh cells) appear to be a particularly fertile “reservoir” for HIV, and scientists are interested in empowering these cells to better fight off HIV.

There are two main types of T cells in the immune system, helper cells and antiviral, killer cells that differ based on the molecules they express on their cell surface and the part they play in the immune system. Normally antiviral T cells do not have access to germinal centers where HIV can persist in an HIV-positive person despite their taking antiretroviral drugs. 

The green areas are B cell follicles within germinal centers, specialized areas of lymph nodes where HIV-infected cells hide out. Red spots indicate antiviral T cells. Credit: Rama Rao Amara, Emory Vaccine Center

However, a new study from the Yerkes National Primate Research Center at Emory University identified a group of antiviral T cells that are essentially given “badge access” into germinal centers, thanks to a molecule expressed on their cell surface called CXCR5. And if CXCR5 is the key to T cell access to germinal centers, is there a way to induce CXCR5 expression on the surface of antiviral T cells? This was the goal of researcher Rama Rao Amara, PhD, with the idea that CXCR5 display would boost the anti-HIV ability of the immune system.

"These cells have the potential to infiltrate sites of ongoing viral replication and persistence," Amara said of Tfh cells, which express CXCR5 on their surface and have access to germinal centers. "Their properties and the ability to induce these cells by vaccination provide a tremendous opportunity to target and reduce the viral reservoir in lymphoid tissues."

Amara and a team of researchers from Emory conducted a study with rhesus macaques, which were vaccinated against SIV, the “monkey version” of HIV, followed by consistent exposure to the virus. While a promising proportion of macaques showed nearly 40 percent of CXCR5-expressing antiviral T cells in their lymph nodes, some of the animals ended up with varying degrees of infection despite being vaccinated against SIV. 

From the study, researchers concluded that the more CXCR5-positive antiviral T cells, the better the immune system’s ability to control the virus, and Amara calls antiviral T cells displaying CXCR5 “functionally superior.” And although sometimes when stimulated, CXCR5-positive cells lose their CXCR5 expression, an immune regulatory molecule called TGF-beta can fix this problem.

They also noticed that the Tfh cells that have natural access to germinal centers by displaying CXCR5 have stem cell-like properties, explained co-corresponding author Vijayakumar Velu, PhD, because they can differentiate into both CXCR5-positive and -negative cells. Interestingly, the same type of cells appear to have been found in mice with other chronic viral infections.

The recent study was published in the journal PNAS.

Source: Emory Health Sciences

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
APR 21, 2020
Drug Discovery & Development
Researchers Develop COVID-19 Nasal Spray Vaccine
APR 21, 2020
Researchers Develop COVID-19 Nasal Spray Vaccine
Researchers from the University of Waterloo in Canada are working on a DNA-based vaccine for COVID-19 that can be applie ...
MAY 19, 2020
Drug Discovery & Development
COVID-19 Vaccine On Track for Late 2020
MAY 19, 2020
COVID-19 Vaccine On Track for Late 2020
Moderna, a biotechnology company based in Massachusetts, has released information on its vaccine against COVID-19 from i ...
JUN 06, 2020
Immunology
Cancer Cell Clusters Better At Resisting the Immune System
JUN 06, 2020
Cancer Cell Clusters Better At Resisting the Immune System
For cancerous cells in the body, it seems there is safety in numbers. Researchers from a newly published study investiga ...
JUN 15, 2020
Drug Discovery & Development
FDA Approves HPV Vaccine to Prevent Throat Cancer
JUN 15, 2020
FDA Approves HPV Vaccine to Prevent Throat Cancer
For around a decade, research has suggested that Gardasil, an HPV vaccine, could prevent throat cancer, a condition that ...
JUL 07, 2020
Coronavirus
No Evidence Showing Asthma Increases Severity of COVID-19
JUL 07, 2020
No Evidence Showing Asthma Increases Severity of COVID-19
Scientists have been scrambling to learn as much as possible about the novel coronavirus, which causes the disease COVID ...
JUL 14, 2020
Coronavirus
What Makes A Strong Antibody Response to Coronavirus
JUL 14, 2020
What Makes A Strong Antibody Response to Coronavirus
Scientists all over the world are racing to develop a vaccine that effectively and safely prompts protective immunity to ...
Loading Comments...